labcorp report third-quart result beat top bottom line narrow
guidanc revenu billion exceed estim consensu
billion adjust ep best estim consensu
first look found diagnost drive modest upsid quarter guidanc
despit beat quarter mix bag diagnost held well notwithstand
unitedhealthcar uhc share-shift quest outperform pama
headwind beat top-lin estim quarter revenu expect
versu year covanc organ growth
howev miss estim full-year revenu outlook lower
although segment oper margin top
estim roughli basi point year-over-year amid plethora move
part model pama manag care share-shift uhc prefer lab network
pln envigo transact lower covanc outlook beaconlb contract nonrenew
add neg color outlook stock year-to-
date enter call market reaction post-ep share intra-day
close reflect investor expect beat-and-rais like quest deliv
tuesday rather number move
diagnost lcd revenu billion target billion
organ volum beat target manag quantifi
headwind roughli basi point manag care contract chang organ
volum exclud chang despit pama headwind
headwind follow uhc nonrenew beaconlb pilot florida
revenu per requisit increas exclud disposit due favor mix
acquisit note third quarter includ one month beaconlb
nonrenew revenu per requisit headwind expect basi point
fourth quarter lcd oper margin fell basi point
estim estim due impact beaconlb nonrenew extra
payrol day quarter call manag note margin less year-
over-year fourth quarter year-to-d period due top-lin growth
on-going effici launchpad initi track toward million net
save
covanc cdd revenu billion target billion
constant-curr revenu growth organ growth versu target
 contribut off-set disposit miss estim
labcorp second-largest independ clinic laboratori unit state nation network
primari laboratori patient servic center compani perform routin laboratori test
specimen day built lead platform esoter test
return equiti ttm
laboratori corpor america hold
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
result highlight ttm book-to-bil second quarter ttm net order
sequenti billion backlog sequenti billion billion expect convert
revenu next month despit miss organ growth number cdd saw roughli basi point margin
improv quarter continu organ growth off-set part higher personnel cost acquisit
launchpad save track toward million net save
payer updat labcorp includ uhc pln launch juli uhc began introduc out-of-pocket polici
effect octob select state begin steer patient volum pln member includ labcorp
call manag note uhc sell pln aso expect addit updat throughout
strategi broadli adopt broadli manag care compani expect unit price flat basi
point line
consum focu walgreen partnership continu expand locat nine state
locat progress track toward long-term goal year-end time manag view
retail strategi complement replac patient servic center psc expect discuss roll-out
beyond psc aspect relationship consumer-initi on-line test platform pixel
expand includ sampl collect phlebotomist psc menu compris test packag
analyt still immateri top/bottom line pixel combin labcorp grow retail footprint
enabl compani particip broader healthcar shift away facility-bas care patient
manag narrow outlook revenu expect grow inclus headwind
divestitur headwind currenc compar previou rang includ
headwind divestitur headwind currenc adjust ep expect
previou rang free cash flow expect million billion unchang
lcd outlook rais revenu expect includ fx headwind basi point
neg impact divestitur compar previou rang pama
headwind lcd revenu growth third quarter compar full-year guidanc basi point
cdd outlook lower revenu expect grow includ basi point fx headwind basi
point compar previou rang
estim includ revenu billion billion adjust ep
estim includ revenu billion billion adjust ep
share trade time adjust ep target three-year averag time view third quarter
miss elev expect remain compel long-term entri point continu believ compani
effort build scale diversifi cro busi leverag labcorp broad patient access lead higher
revenu growth case covanc independ diagnost side intrigu potenti
rapidli grow walgreen collabor continu believ earli inning secular shift market
share lower-cost larger lab given medicar reimburs pressur increas effort part privat
payer reduc lab spend strateg way compani deliv solid execut year-to-d despit face
steepest year pama cut uhc share loss beaconlb nonrenew expect investor continu get
comfort ep rang long-term growth outlook maintain outperform rate
exhibit summar chang made model follow labcorp third-quart confer call
summari financi model present pleas contact william blair sale repres receiv full
chang model million except per share data previou estimatechangecurr guidanceprevi estimatechangecurr estimaterevenu labcorp covanc drug total y/i growth bp bp gross gross margin bp bp ebitda margin bp bp growth bp bp oper interest expens incom equiti pre-tax incom tax effect tax rate bp bp adjust net dilut share adjust consensu sourc compani report william blair compani estim factsetnot summari tabl line item adjust includ number may william blair
labcorp lh rate outperformsummari financi result ratio million except gross adjust depreci interest expens pre-tax incom minor share adjust net adjust dilut share margin analysi gross ebitda tax growthrevenu sheet statist total total sharehold invest capit total debt plu total oper cash capit free cash per ttm interest coveragetot debt ebitda net debt ebitda debt debt total ebitda net interest matt larew summari tabl line item adjust includ number may sum import disclosur
